Clinical outlook for type-1 and FOXP3+ T regulatory cell-based therapy

Silvia Gregori, Laura Passerini, Maria Grazia Roncarolo

Research output: Contribution to journalArticlepeer-review


T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and efficacy of Treg-based therapies in humans. Despite promising results, a number of issues remain to be solved. We will discuss the results obtained from clinical trials and the challenges and risks we are facing in the further development of Treg-based therapies.

Original languageEnglish
Article number593
JournalFrontiers in Immunology
Issue numberNOV
Publication statusPublished - 2015


  • FOXP3
  • Gene transfer
  • IL-10
  • T regulatory cells
  • T regulatory type 1 cells
  • Tolerance
  • Treg-based therapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Clinical outlook for type-1 and FOXP3+ T regulatory cell-based therapy'. Together they form a unique fingerprint.

Cite this